NUVARING Safety Questions, NUVARING Answers


More Here>>Side Effects - FDA Reports 2006-2008

Medications A-Z:   A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Welcome! Patientsville.com provides unique information about NUVARING. Our extensive database of NUVARING adverse events and NUVARING warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.

>> Announcements
Check out our Hospital and Home Care Quality Reports.

Ask Our Health Experts about NUVARING

Do You Have a Question about Your Health?

Our Doctors and Nurses will Help You Understand Your Symptoms and Feel Better!
Private, Confidential and Discreet



NUVARING Safety Reports

Total NUVARING reports: 341.
NUVARING FDA safety alerts: No.
Reported deaths: 6    Reported hospitalizations: 161.
Take NUVARING Side Effects Survey or Share Your NUVARING Story. NUVARING Usage.

< Previous  Showing 151-225 of 341 Next >

Physician from UNITED STATES reported NUVARING problem on Mar 14, 2007. Female patient, 45 years of age, weighting 154.1 lb, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: cerebral thrombosis, haemorrhage intracranial. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on Mar 13, 2007. Female patient, 24 years of age, weighting 123.5 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: nausea, salpingitis, vomiting, vulvovaginal mycotic infection. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Mar 15, 2007. Female patient, 23 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: ill-defined disorder. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from GERMANY on Mar 15, 2007. Female patient, 26 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: anti-hbs antibody positive, focal nodular hyperplasia, hepatic steatosis, hepatitis a antigen positive, hepatomegaly, liver disorder, lymphadenopathy. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Mar 21, 2007. Female patient, 29 years of age, weighting 175.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: factor v leiden mutation, pulmonary embolism. NUVARING dosage: unknown. During the same period patient was treated with LEVAQUIN. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from AUSTRIA on Mar 28, 2007. Female patient, 16 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: acute respiratory distress syndrome, arthralgia, meningism, neck pain, oophoritis, peritonitis, salpingitis, toxic shock syndrome streptococcal. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Mar 22, 2007. Female patient was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: hypersensitivity, pain, vaginal discharge. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Health Professional from UNITED STATES on Apr 09, 2007. Female patient, 47 years of age, weighting 214.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from CANADA reported NUVARING problem on Mar 27, 2007. Female patient was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: fungal infection, mood swings. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Health Professional from UNITED STATES on Mar 28, 2007. Female patient, 20 years of age, weighting 155.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: dizziness, headache, hypoaesthesia, speech disorder, vision blurred, vomiting. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Apr 13, 2007. Female patient, weighting 200.0 lb, was diagnosed with contraception, menstruation irregular and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: thrombosis. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 13, 2007. Female patient, 35 years of age, weighting 210.0 lb, was diagnosed with polycystic ovaries and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: blood fibrinogen decreased, contusion, deep vein thrombosis, weight increased. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from NETHERLANDS reported NUVARING problem on Apr 03, 2007. Female patient, 27 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: cervical dysplasia. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 19, 2007. Female patient, 39 years of age, weighting 250.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: deep vein thrombosis, pulmonary embolism. NUVARING dosage: unknown. Patient was hospitalized and became disabled. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Apr 19, 2007. Female patient, 28 years of age, weighting 135.0 lb, was diagnosed with contraception, dysmenorrhoea and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: deep vein thrombosis, pulmonary embolism, treatment noncompliance. NUVARING dosage: .120 MG/DAY VAG. During the same period patient was treated with VANIQA CREAM. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Health Professional from UNITED STATES on Apr 20, 2007. Female patient, 28 years of age, weighting 130.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: bacterial infection, dyspareunia, fungal infection, muscle spasms, vaginal discharge, vulvovaginal dryness. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Apr 05, 2007. Male patient, weighting 8.62 lb, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: jaundice neonatal, pregnancy with contraceptive device. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Pharmacist from UNITED STATES on Apr 27, 2007. Female patient, 21 years of age, weighting 224.9 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: chest pain, coagulopathy, dyspnoea, hyperhidrosis, pulmonary embolism. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from FRANCE reported NUVARING problem on Apr 12, 2007. Female patient, 27 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: gynaecological chlamydia infection, pyrexia. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from CANADA on Apr 17, 2007. Female patient, 25 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: blood creatine phosphokinase increased, contusion, convulsion, fall, headache, loss of consciousness. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Apr 13, 2007. Female patient, 34 years of age, weighting 119.9 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: hepatitis c. NUVARING dosage: unknown. During the same period patient was treated with AZMACORT, PREVACID. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 19, 2007. Female patient, 25 years of age, weighting 127.0 lb, was diagnosed with contraception, menstruation irregular and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: papilloma viral infection, smear cervix abnormal. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from PORTUGAL reported NUVARING problem on Apr 20, 2007. Female patient, 37 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: urinary incontinence. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Health Professional from UNITED STATES on Apr 20, 2007. Female patient, 27 years of age, weighting 130.1 lb, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: inflammation, medical device complication, vaginal discharge, vaginal dysplasia. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from NETHERLANDS reported NUVARING problem on Apr 24, 2007. Female patient, 29 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: ovarian cyst. NUVARING dosage: unknown. During the same period patient was treated with SUMATRIPTAN SUCCINATE. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 25, 2007. Female patient, 45 years of age, weighting 130.1 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: anxiety, apathy, depression, fluid retention, lethargy, menorrhagia, stress, suicidal ideation. NUVARING dosage: unknown. During the same period patient was treated with CHEWABLE VITAMIN, VITAMIN E. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Apr 27, 2007. Female patient, 29 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: haemoptysis. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 25, 2007. Female patient, 24 years of age, weighting 135.4 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: anxiety, asthenia, depression, disorientation, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, somnolence, tremor. NUVARING dosage: unknown. During the same period patient was treated with KEPPRA, TRILEPTAL, BETASERON. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from CANADA reported NUVARING problem on Apr 27, 2007. Female patient, 25 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: blood creatine phosphokinase increased, contusion, convulsion, fall, headache, muscle tightness, tongue biting. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on May 01, 2007. Female patient, 24 years of age, weighting 123.5 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: cyst, endometrial disorder, endometriosis, nausea, vomiting, vulvovaginal mycotic infection. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from SPAIN reported NUVARING problem on May 08, 2007. Female patient, 22 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: abdominal pain. NUVARING dosage: unknown. During the same period patient was treated with IBUPROFEN, CLONIXIN LYSINATE. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on May 04, 2007. Female patient, 29 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: bronchitis, condition aggravated, haematemesis. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on May 14, 2007. Female patient, 38 years of age, weighting 207.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: convulsion, vulvovaginal mycotic infection. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on May 18, 2007. Female patient was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: unevaluable event. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on May 18, 2007. Female patient, 34 years of age, weighting 119.9 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: hepatitis c. NUVARING dosage: unknown. During the same period patient was treated with AZMACORT, PREVACID. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on May 23, 2007. Female patient, 38 years of age, weighting 207.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: convulsion, vulvovaginal mycotic infection. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Nov 02, 2006. Female patient, 20 years of age, weighting 127.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: smear cervix abnormal. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on May 24, 2007. Female patient, 27 years of age, weighting 149.9 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: endometrial disorder, smear cervix abnormal. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on June 12, 2007. Female patient, 21 years of age, weighting 140.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: abdominal pain upper, anger, contraceptive device complication, depression, fatigue, mass, muscle spasms, thrombosis. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Physician from UNITED STATES on May 30, 2007. Female patient, 43 years of age, weighting 129.0 lb, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: abdominal pain, abdominal rebound tenderness, haemorrhage, vulvovaginal mycotic infection. NUVARING dosage: unknown. During the same period patient was treated with TRAZODONE. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on May 30, 2007. Female patient, 27 years of age, weighting 149.9 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: smear cervix abnormal. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on May 30, 2007. Female patient, 45 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: headache, hypertension, hypoaesthesia, jaw disorder. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on June 13, 2007. Female patient, 19 years of age, weighting 230.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism. NUVARING dosage: unknown. During the same period patient was treated with ZOLOFT. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on June 18, 2007. Female patient, 36 years of age, weighting 154.0 lb, was diagnosed with menorrhagia and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: deep vein thrombosis, liposuction, post procedural complication, pulmonary embolism. NUVARING dosage: unknown. Patient was hospitalized and became disabled. Patient recovered.

Physician from UNITED STATES reported NUVARING problem on June 08, 2007. Female patient, 43 years of age, weighting 129.0 lb, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: abdominal pain, abdominal rebound tenderness, vaginal erythema, vaginal inflammation, vaginal oedema, vulvovaginal mycotic infection. NUVARING dosage: unknown. During the same period patient was treated with TRAZODONE. Patient recovered.

NUVARING problem was reported by a Pharmacist from UNITED STATES on June 19, 2007. Female patient, 26 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: haemoptysis, pleurisy, pulmonary embolism. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on June 21, 2007. Female patient, 38 years of age, weighting 131.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: micturition urgency, vaginal burning sensation, weight increased. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on June 29, 2007. Female patient, 22 years of age, weighting 102.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: blood glucose fluctuation, hypoglycaemia, libido decreased, wheezing. NUVARING dosage: unknown. During the same period patient was treated with PROAIR HFA. Patient recovered.

Pharmacist from UNITED STATES reported NUVARING problem on June 29, 2007. Female patient, 23 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Health Professional from GERMANY on June 23, 2006. Female patient was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: implant site fibrosis, injury. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from CANADA reported NUVARING problem on June 26, 2006. Female patient, 34 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: crying, depression, fatigue. NUVARING dosage: unknown. During the same period patient was treated with PROPRANOLOL HYDROCHLORIDE, SUMATRIPTAN SUCCINATE. Patient recovered.

NUVARING problem was reported by a Health Professional from CANADA on June 26, 2006. Female patient, 29 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: deep vein thrombosis. NUVARING dosage: unknown. During the same period patient was treated with ORTHO EVRA. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on June 27, 2006. Female patient, 24 years of age, was diagnosed with contraception, hepatitis c and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: back pain, metrorrhagia, nausea, uterine spasm, white blood cell count decreased. NUVARING dosage: unknown. During the same period patient was treated with RIBAVIRIN, LEVAQUIN, LEXAPRO. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Physician from UNITED STATES on June 27, 2006. Female patient, 25 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: cerebral thrombosis, cerebrovascular accident. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on June 27, 2006. Female patient, 29 years of age, weighting 145.1 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: anxiety, headache, panic attack. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on July 03, 2006. Female patient, 26 years of age, weighting 123.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: convulsion, metrorrhagia. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Physician from UNITED STATES reported NUVARING problem on July 18, 2006. Female patient, weighting 166.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: back pain, decreased activity. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on July 07, 2006. Female patient, 34 years of age, weighting 130.1 lb, was diagnosed with menstrual disorder and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: blood pressure increased, contusion, depression, flank pain, food craving, heart rate increased, metal poisoning, oedema peripheral, paraesthesia. NUVARING dosage: unknown. During the same period patient was treated with IBUPROFEN, ASPIRIN. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on July 03, 2006. Female patient was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: deep vein thrombosis. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Physician from UNITED STATES on July 07, 2006. Female patient, 37 years of age, weighting 145.1 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: ectopic pregnancy, pelvic pain, pregnancy with contraceptive device. NUVARING dosage: unknown. Patient recovered.

Physician from UNITED STATES reported NUVARING problem on July 08, 2006. Female patient, 51 years of age, weighting 138.0 lb, was diagnosed with menstrual disorder and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: adhesion, complication of device removal, vaginal disorder. NUVARING dosage: unknown. During the same period patient was treated with LUNESTA, DETROL LA. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from RUSSIAN FEDERATION on July 07, 2006. Female patient was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: uterine cancer. NUVARING dosage: unknown. Patient recovered.

Pharmacist from UNITED STATES reported NUVARING problem on July 25, 2006. Female patient, 40 years of age, weighting 178.6 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: back pain, chest pain, cough, dyspnoea, fall, hypoaesthesia, pleuritic pain, pyrexia. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from GERMANY on July 24, 2006. Female patient was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: colitis ulcerative, stress. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on July 18, 2006. Female patient, 24 years of age, was diagnosed with contraception, hepatitis c and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: anxiety, back pain, nausea, uterine spasm, vaginal haemorrhage, white blood cell count decreased. NUVARING dosage: unknown. During the same period patient was treated with RIBAVIRIN, LEVAQUIN, LEXAPRO. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Physician from UNITED STATES on Aug 11, 2006. Female patient, 31 years of age, weighting 149.9 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: flank pain, pulmonary embolism, splenic infarction. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on July 28, 2006. Female patient, 33 years of age, weighting 135.4 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: oral candidiasis, pneumonia aspiration. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from SWITZERLAND on July 31, 2006. Female patient, 23 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: behcet's syndrome, transaminases increased, vaginal discharge. NUVARING dosage: unknown. Patient was hospitalized. Patient recovered.

Health Professional from GERMANY reported NUVARING problem on Aug 18, 2006. Female patient, 47 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: crohn's disease, stress. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 15, 2006. Female patient, 23 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: cardio-respiratory arrest, depressed level of consciousness, fall, nervous system disorder, pyrexia, white blood cell count increased, wolff-parkinson-white syndrome. NUVARING dosage: unknown. Patient was hospitalized and became disabled. Patient recovered.

Consumer or non-health professional from NETHERLANDS reported NUVARING problem on Aug 01, 2006. Female patient was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism. NUVARING dosage: unknown. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from NETHERLANDS on Aug 14, 2006. Female patient was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: respiratory disorder. NUVARING dosage: unknown. Patient recovered.

Consumer or non-health professional from BRAZIL reported NUVARING problem on Aug 21, 2006. Female patient, 32 years of age, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: myocardial infarction. NUVARING dosage: unknown. During the same period patient was treated with HYZAAR. Patient was hospitalized. Patient recovered.

NUVARING problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 15, 2006. Female patient, 31 years of age, weighting 116.0 lb, was diagnosed with contraception and was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: calcinosis, metrorrhagia, nephrolithiasis. NUVARING dosage: unknown. During the same period patient was treated with ZOLOFT. Patient recovered.

Consumer or non-health professional from UNITED STATES reported NUVARING problem on Aug 21, 2006. Female patient, 31 years of age, was treated with NUVARING. After drug was administered, patient experienced the following problems/side effects: appendicectomy. NUVARING dosage: unknown. Patient recovered.

< Previous  Showing 151-225 of 341 Next >

Ask Our Patient Community about NUVARING

Select a Medication and Click to Access Reports about Side Effects and Adverse Reactions

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z
This drug has as active FDA Safety Alert This drug has an active FDA Safety Alert
A
Abacavir sulfate
Abatacept
Abilify
Acamprosate calcium
AccuprilThis drug has as active FDA Safety Alert
AccutaneThis drug has as active FDA Safety Alert
AceonThis drug has as active FDA Safety Alert
Aciphex
Actiq (fentanyl citrate)
ActimmuneThis drug has as active FDA Safety Alert (aripiprazole) (quinapril) (isotretinoin) (perindopril) (rabeprazole) (interferon gamma-1b)
ActonelThis drug has as active FDA Safety Alert (risedronate)
Actoplus MetThis drug has as active FDA Safety Alert (pioglitazone)
ActosThis drug has as active FDA Safety Alert (pioglitazone)
AcuTect (technetium Tc 99m apcitide)
Adefovir dipivoxil
Advair Diskus(Fluticasone propionate; Salmeterol xinafoate)
AdderallThis drug has as active FDA Safety Alert (amphetamine salts)
Agenerase (amprenavir)
Aggrastat (tirofiban)
Alamast (pemirolast)
AlendronateThis drug has as active FDA Safety Alert
AlemtuzumabThis drug has as active FDA Safety Alert
AleveThis drug has as active FDA Safety Alert (naproxen sodium)
Alfuzosin
Alinia (nitazoxanide)
Alimta (pemetrexed)
Alitretinoin
Almotriptan malateThis drug has as active FDA Safety Alert
Alosetron hydrochloride
Aloxi (palonosetron)
Alrex (loteprednol etabonate)
AltaceThis drug has as active FDA Safety Alert (ramipril)
Ambien (zolpidem tartrate)
AmergeThis drug has as active FDA Safety Alert (naratriptan)
Aminolevulinic acid
AmiodaroneThis drug has as active FDA Safety Alert
Amitiza (lubiprostone)
AmnesteemThis drug has as active FDA Safety Alert (isotretinoin)
Amphadase (hyaluronidase)
luronidase)
Amphetamine saltsThis drug has as active FDA Safety Alert
Amprenavir
AnaproxThis drug has as active FDA Safety Alert (naproxen sodium)
Angiomax (bivalirudin)
Anidulafungin
Antagon (ganirelix acetate)
Anthelios SX (avobenzone, ecamsule, octocrylene)
Apidra (insulin glulisine recombinant)
Apokyn (apomorphine)
Aprepitant
Aprotinin
Aptivus (tipranavir)
AranespThis drug has as active FDA Safety Alert (darbepoetin alpha)
Arava (leflunomide)
Arformoterol
Argatroban
ArediaThis drug has as active FDA Safety Alert (pamidronate)
Aripiprazole
Arixtra (fondaparinux)
Aromasin (exemestane)
Arranon (nelarabine)
Arsenic trioxide
Aspirin
Atacand (candesartan cilexetil)
Atazanavir sulfate
AtomoxetineThis drug has as active FDA Safety Alert
Avastin (bevacizumab)
Avelox (moxifloxacin)
Avobenzone, Ecamsule, Octocrylene
Avodart (dutasteride)
Avonex (interferon beta-1a)
AxertThis drug has as active FDA Safety Alert (almotriptan malate)
Azacitidine
Azilect (rasagiline)
Azopt (brinzolamide)

back to top

B
Balsalazide disodium
Baraclude (entecavir)
BenazeprilThis drug has as active FDA Safety Alert
Benicar (olmesartan medoxomil)
Bevacizumab
Bexarotene
BextraThis drug has as active FDA Safety Alert (valdecoxib)
BiaxinThis drug has as active FDA Safety Alert (clarithromycin)
Bimatoprost
Bivalirudin
BonivaThis drug has as active FDA Safety Alert (ibandronate)
Bortezomib
Brinzolamide
Brovana (arformoterol)
BupropionThis drug has as active FDA Safety Alert
Butisol sodium
Byetta (exenatide)


back to top

C
Calfactant
CampathThis drug has as active FDA Safety Alert (alemtuzumab)
Campral (acamprosate calcium)
Cancidas (caspofungin)
Candesartan cilexetil
Capecitabine
CapotenThis drug has as active FDA Safety Alert (captopril)
CaptoprilThis drug has as active FDA Safety Alert
CarbamazepineThis drug has as active FDA Safety Alert
CarbatrolThis drug has as active FDA Safety Alert (carbamazepine)
Carbrital (pentobarbital and carbromal)
Caspofungin
Cefditoren pivoxil
CefepimeThis drug has as active FDA Safety Alert
CeftriaxoneThis drug has as active FDA Safety Alert
CelebrexThis drug has as active FDA Safety Alert (celecoxib)
CelecoxibThis drug has as active FDA Safety Alert
CelexaThis drug has as active FDA Safety Alert (citalopram hydrobromide)
Cetrorelix acetate
Cetrotide (cetrorelix acetate)
Cetuximab
Cevimeline
ChantixThis drug has as active FDA Safety Alert (varenicline)
Cialis (tadalafil)
Cilostazol
Cinacalcet
Cirlesonide
CitalopramThis drug has as active FDA Safety Alert
ClaravisThis drug has as active FDA Safety Alert (isotretinoin)
ClarithromycinThis drug has as active FDA Safety Alert
Clarinex (desloratadine)
Clolar (clofarabine)
Clofarabine
Clozapine
Clozaril (clozapine)
CodeineThis drug has as active FDA Safety Alert
Colazal (balsalazide disodium)
Colesevelam
ColistimethateThis drug has as active FDA Safety Alert
Coly-Mycin M (colistimethate)This drug has as active FDA Safety Alert
Comtan (entacapone)
Concerta (methylphenidate)
Conivaptan
CordaroneThis drug has as active FDA Safety Alert (amiodarone)
CrestorThis drug has as active FDA Safety Alert (rosuvastatin calcium)
Cubicin (daptomycin)
Curosurf (poractant alfa)
CylertThis drug has as active FDA Safety Alert (pemoline)
CymbaltaThis drug has as active FDA Safety Alert (duloxetine)
CytotecThis drug has as active FDA Safety Alert (misoprostol)

back to top

D
Dacogen (decitabine)
Dalfopristin
Dalmane (flurazepam)
Daptomycin
Darbepoetin alphaThis drug has as active FDA Safety Alert
Darifenacin
Darunavir
Dasatinib
Daytrana (methylphenidate transdermal)
DDAVPThis drug has as active FDA Safety Alert (desmopressin)
DDAVP Nasal SprayThis drug has as active FDA Safety Alert (demopressin)
DDAVP Rhinal TubeThis drug has as active FDA Safety Alert (desmopressin)
DDVPThis drug has as active FDA Safety Alert (desmopressin
Decitabine
Deferasirox
Definity (perflutren lipid microspheres)
DepaconThis drug has as active FDA Safety Alert (valproate)
DepakeneThis drug has as active FDA Safety Alert (valproate)
DepakoteThis drug has as active FDA Safety Alert (valproate)
Desloratadine
DesmopressinThis drug has as active FDA Safety Alert
Detrol (tolterodine tartrate)
terodine tartrate)
Dexedrine (dextroamphetamine sulfate)
Dexmedetomidine
Dexmethylphenidate HCl
> Dextroamphetamine sulfate
Diastat AcuDialThis drug has as active FDA Safety Alert
Diazepam rectal gelThis drug has as active FDA Safety Alert
DidronelThis drug has as active FDA Safety Alert (etidronate)
DiprivanThis drug has as active FDA Safety Alert (propofol)
Dofetilide
Doral (quazepam)
Doxercalcif
Drospirenone
DuloxetineThis drug has as active FDA Safety Alert
DuragesicThis drug has as active FDA Safety Alert (fentanyl transdermal system)
Dutasteride

back to top

E

Eculizumab
Edetate disodium
Efalizumab
Efavirenz
EffexorThis drug has as active FDA Safety Alert (venlafaxine)
Elestat (epinastine)
EletriptanThis drug has as active FDA Safety Alert
Elidel (pimecrolimus)
Ellence (epirubicin)
Eloxatin (oxaliplatin)
Emend (aprepitant)
Emtricitabine
Emtriva (emtricitabine)
Enablex (darifenacin)
Enalapril / EnalaprilatThis drug has as active FDA Safety Alert
Endrate (edetate disodium)
Enfuvirtide
Entacapone
Entecavir
Epinastine
Epirubicin
Eplerenone
Epoetin alfaThis drug has as active FDA Safety Alert
EpogenThis drug has as active FDA Safety Alert (epoetin alfa)
Eptifibatide
EquetroThis drug has as active FDA Safety Alert (carbamazepine)
Eraxis (anidulafungin)
Erbitux (cetuximab)
Ertaczo (sertaconazole)
EscitalopramThis drug has as active FDA Safety Alert
Estazolam
Eszopiclone
Ethchlorvynol
Ethinyl estradiol
EtidronateThis drug has as active FDA Safety Alert
Evoxac (cevimeline)
Exelon (rivastigmine tartrate)
Exenatide
Exjade (deferasirox)
Exemestane
Extraneal (icodextrin)
Ezetimibe
Ezetimibe/simvastatin

back to top

 F
Factive (gemifloxacin mesylate)
Faslodex (fulvestrant)
FelbamateThis drug has as active FDA Safety Alert
FelbatolThis drug has as active FDA Safety Alert (felbamate)
Fentanyl buccal tabletsThis drug has as active FDA Safety Alert
Fentanyl citrate
Fentanyl transdermal systemThis drug has as active FDA Safety Alert
FentoraThis drug has as active FDA Safety Alert (fentanyl buccal tablets)
Ferrlecit (sodium ferric gluconate complex)
Fleet Accu-PrepThis drug has as active FDA Safety Alert (sodium phosphate)
Fleet Phospho-SodaThis drug has as active FDA Safety Alert (sodium phosphate)
FluoxetineThis drug has as active FDA Safety Alert
Flurazepam
Fluticasone propionate
FluvoxamineThis drug has as active FDA Safety Alert
Focalin (dexmethylphenidate)
Focalin XR (dexmethylphenidate)
Fomivirsen
Fondaparinux
Foradil (formoterol fumarate)
Formoterol fumarate
FosamaxThis drug has as active FDA Safety Alert (alendronate)
FosinoprilThis drug has as active FDA Safety Alert
FrovaThis drug has as active FDA Safety Alert (frovatriptan succinate)
Frovatriptan succinateThis drug has as active FDA Safety Alert
Fulvestrant
Fuzeon (enfuvirtide)

G
GabapentinThis drug has as active FDA Safety Alert
GabitrilThis drug has as active FDA Safety Alert (tiagabine)
Gadobenate DimeglumineThis drug has as active FDA Safety Alert
GadodiamideThis drug has as active FDA Safety Alert
GadoliniumThis drug has as active FDA Safety Alert
Gadopentetate DimeglumineThis drug has as active FDA Safety Alert
GadoteridolThis drug has as active FDA Safety Alert
GadoversetamideThis drug has as active FDA Safety Alert
GalantamineThis drug has as active FDA Safety Alert
Ganirelix acetate
GatifloxacinThis drug has as active FDA Safety Alert
GefitinibThis drug has as active FDA Safety Alert
Gemifloxacin mesylate
Gemtuzumab ozogamicin
Geodon (ziprasidone)
Gleevec (imatinib mesylate)

back to top

H
Halcion (triazolam)
HaldolThis drug has as active FDA Safety Alert (haloperidol)
HaloperidolThis drug has as active FDA Safety Alert
Hectorol (doxercalcif)
Hepsera (adefovir dipivoxil)
Hyaluronidase
Hydase (hyaluronidase)
Human Secretin

back to top

I
IbandronateThis drug has as active FDA Safety Alert
Ibuprofen
Icodextrin
Iloprost
Imatinib mesylate
Increlex (Mecasermin [rDNA origin]
Infasurf Preservative Free (calfactant)
ImitrexThis drug has as active FDA Safety Alert (sumatriptan)
Innohep (tinzaparin)
Inspra (eplerenone)
Insulin Aspart recombinant
Insulin Detemir recombinant
Insulin Glargine recombinant
Insulin Glulisine recombinant
Intron A (interferon alfa-2b)
Integrilin (eptifibatide)
ifibatide)
Interferon alfa-2b
Interferon beta-1a
Interferon gamma-1bThis drug has as active FDA Safety Alert
Invega (paliperidone)
Iplex  (mecasermin rinfabate)
IressaThis drug has as active FDA Safety Alert (gefitinib)
IsotretinoinThis drug has as active FDA Safety Alert

back to top

J
Januvia (sitagliptin phosphate)

back to top

K
Kaletra (lopinavir; ritonavir)
Kepivance (palifermin)
KeppraThis drug has as active FDA Safety Alert (levetiracetam)
Ketek (telithromycin)
Ketotifen fumarate

back to top

L
LamictalThis drug has as active FDA Safety Alert (lamotrigine)
LamotrigineThis drug has as active FDA Safety Alert
Lantus (insulin glargine recombinant)
Leflunomide
Lenalidomide
Lepirudin recombinant
Levalbuterol
Levemir (insulin detemir recombinant)
LevetiracetamThis drug has as active FDA Safety Alert
Levitra (vardenafil)
Levonorgestrel
Levothyroxine sodium
Levulan Kerastick (aminolevulinic acid)
LexaproThis drug has as active FDA Safety Alert (escitalopram)
Lindane
LinezolidThis drug has as active FDA Safety Alert
LisinoprilThis drug has as active FDA Safety Alert
Lopinavir/ritonavir
Lotemax (loteprednol etabonate)
LotensinThis drug has as active FDA Safety Alert (benazepril)
Loteprednol etabonate
Lotronex (alosetron hydrochloride)
Lubiprostone
Lucentis (ranibizumab)
Lumigan (bimatoprost)
Lunestra (eszopiclone)
LyricaThis drug has as active FDA Safety Alert (pregabalin)

back to top

M
Macugen (pegaptanib)
MagnevistThis drug has as active FDA Safety Alert (gadopentetate dimeglumine)
Maraviroc
MavikThis drug has as active FDA Safety Alert (trandolapril)
MaxaltThis drug has as active FDA Safety Alert (rizatriptan benzoate)
MaxipimeThis drug has as active FDA Safety Alert (cefepime)
Mecasermin [rDNA origin]
Mecasermin-rinfabate
Meloxicam
Memantine
Metadate CD (methylphenidate HCl)
ylphenidate HCl)
Methylphenidate HCl
Methylphenidate transdermal
Mequinol
Micafungin
Micardis (telmisartan)
misartan)
MifeprexThis drug has as active FDA Safety Alert (mifepristone)
MifepristoneThis drug has as active FDA Safety Alert
Miglustat
MinirinThis drug has as active FDA Safety Alert (desmopressin)
MirtazapineThis drug has as active FDA Safety Alert
MisoprostolThis drug has as active FDA Safety Alert
Mobic (meloxicam)
Modafinil
MoexiprilThis drug has as active FDA Safety Alert
MonoprilThis drug has as active FDA Safety Alert (fosinopril)
Moxifloxacin
MultiHanceThis drug has as active FDA Safety Alert (gadobenate dimeglumine)
Mycamine (micafungin)
Mylotarg (gemtuzumab ozogamicin)

back to top

N
Namenda (memantine)
NaprosynThis drug has as active FDA Safety Alert (naproxen)
NaproxenThis drug has as active FDA Safety Alert
Naratriptan
Nesiritide recombinant
Nateglinide
Natrecor (nesiritide recombinant)
NefazodoneThis drug has as active FDA Safety Alert
Nelarabine
NeoTect Kit (technetium Tc 99m depreotide)
Nesiritide recombinant
NeurontinThis drug has as active FDA Safety Alert (gabapentin)
Nexavar (sorafenib)
Nitazoxanide
Nitisinone
Norelgestromin
NovoLog (insulin aspart recombinant)
Noxafil (posaconazole)

back to top

O
Olanzapine
Olanzapine/fluoxetineThis drug has as active FDA Safety Alert
Olmesartan medoxomil
Omacor (omega-3-acid ethyl esters)
OmalizumabThis drug has as active FDA Safety Alert
Omega-3-acid ethyl esters
Omnaris (cirlesonide)
OmniscanThis drug has as active FDA Safety Alert (gadodiamide)
OptiMARK (gadoversetamide)
Optison (perflutren protein-type A microspheres)
Orencia (abatacept)
Orfadin (nitisinone)
Orlistat
Ortho Evra (norelgestromin; ethinyl estradiol)
Oseltamivir phosphate
OsmoprepThis drug has as active FDA Safety Alert (sodium phosphate)
Oxaliplatin
OxcarbazepineThis drug has as active FDA Safety Alert


back to top

P
PaceroneThis drug has as active FDA Safety Alert (amiodarone)
Palifermin
Paliperidone
PamidronateThis drug has as active FDA Safety Alert
Panitumumab
Panretin Gel (alitretinoin)
Pantoprazole
Paricalcitol
ParoxetineThis drug has as active FDA Safety Alert
PaxilThis drug has as active FDA Safety Alert (paroxetine)
Pegaptanib
Pegvisomant
Pemetrexed
PemolineThis drug has as active FDA Safety Alert
Pentobarbital and carbromal
Perflutren lipid microspheres
PerindoprilThis drug has as active FDA Safety Alert
PhenerganThis drug has as active FDA Safety Alert (promethazine)
Pimecrolimus
PioglitazoneThis drug has as active FDA Safety Alert
Placidyl (ethchlorvynol)
Plan B (levonorgestrel)
Pletal (cilostazol)
Poractant alfa
Posaconazole
Pramlintide Acetate
Precedex (dexmedetomidine)
PregabalinThis drug has as active FDA Safety Alert
Prezista (darunavir)
Prialt (ziconotide)
Priftin (rifapentine)
PrinivilThis drug has as active FDA Safety Alert (lisinopril)
ProcritThis drug has as active FDA Safety Alert (epoetin alfa)
ProHanceThis drug has as active FDA Safety Alert (gadoteridol)
PromethazineThis drug has as active FDA Safety Alert
PropofolThis drug has as active FDA Safety Alert
Prosom (estazolam)
Protonix (pantoprazole)
Protopic (tacrolimus)
Provigil (modafinil)
ProzacThis drug has as active FDA Safety Alert (fluoxetine)
Prussian blue


back to top

 Q
Quazepam
Quetiapine
QuinaprilThis drug has as active FDA Safety Alert
Quinupristin

R
Rabeprazole
Radiogardase (prussian blue)
Ramelteon
RamiprilThis drug has as active FDA Safety Alert
Ranexa (ranolazine)
Ranibizumab
Ranolazine
Rapamune (sirolimus)
Raptiva (efalizumab)
Rasagiline
RazadyneThis drug has as active FDA Safety Alert (galantamine)
Rebetol (ribavirin)
ReclastThis drug has as active FDA Safety Alert (zoledronic acid)
Refludan (lepirudin recombinant)
Relenza (zanamivir)
Relpax